全文获取类型
收费全文 | 16021篇 |
免费 | 1004篇 |
国内免费 | 66篇 |
专业分类
耳鼻咽喉 | 203篇 |
儿科学 | 482篇 |
妇产科学 | 406篇 |
基础医学 | 3189篇 |
口腔科学 | 319篇 |
临床医学 | 1352篇 |
内科学 | 3146篇 |
皮肤病学 | 502篇 |
神经病学 | 1315篇 |
特种医学 | 749篇 |
外国民族医学 | 2篇 |
外科学 | 2350篇 |
综合类 | 117篇 |
一般理论 | 9篇 |
预防医学 | 923篇 |
眼科学 | 223篇 |
药学 | 992篇 |
中国医学 | 12篇 |
肿瘤学 | 800篇 |
出版年
2021年 | 193篇 |
2020年 | 143篇 |
2019年 | 181篇 |
2018年 | 212篇 |
2017年 | 213篇 |
2016年 | 269篇 |
2015年 | 243篇 |
2014年 | 354篇 |
2013年 | 500篇 |
2012年 | 652篇 |
2011年 | 671篇 |
2010年 | 369篇 |
2009年 | 423篇 |
2008年 | 633篇 |
2007年 | 663篇 |
2006年 | 636篇 |
2005年 | 619篇 |
2004年 | 566篇 |
2003年 | 542篇 |
2002年 | 598篇 |
2001年 | 553篇 |
2000年 | 495篇 |
1999年 | 452篇 |
1998年 | 164篇 |
1997年 | 153篇 |
1996年 | 175篇 |
1995年 | 122篇 |
1994年 | 136篇 |
1993年 | 134篇 |
1992年 | 238篇 |
1991年 | 302篇 |
1990年 | 268篇 |
1989年 | 282篇 |
1988年 | 256篇 |
1987年 | 235篇 |
1986年 | 247篇 |
1985年 | 255篇 |
1984年 | 166篇 |
1983年 | 156篇 |
1982年 | 104篇 |
1980年 | 114篇 |
1979年 | 195篇 |
1978年 | 129篇 |
1977年 | 119篇 |
1976年 | 106篇 |
1975年 | 146篇 |
1974年 | 151篇 |
1973年 | 134篇 |
1972年 | 133篇 |
1971年 | 117篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Andreu Porta-Sánchez Andrew C.T. Ha Xuesong Wang Fahad Almehmadi Peter C. Austin Hadas D. Fischer Atif Al-Qubbany Diego Chemello Vijay Chauhan Eugene Downar Douglas S. Lee Kumaraswamy Nanthakumar 《The Canadian journal of cardiology》2019,35(2):169-177
Background
Catheter ablation of ventricular tachycardia (VT) can reduce the burden of ventricular arrhythmia (VA) but its effect on health care utilization and costs after such therapy is poorly known. We sought to compare the rates of cardiovascular (CV)-related hospitalizations, survival, and health care costs in patients with recurrent VT treated either with VT ablation or with medical therapy.Methods
One-hundred implantable cardioverter-defibrillator patients with structural heart disease who underwent VT ablation were included. Propensity score-matched patients with recurrent VT treated with medical therapy were identified from a prospective registry of approximately 7000 de novo implantable cardioverter-defibrillator patients. Outcomes and costs were ascertained using health administrative databases.Results
Among patients who underwent VT ablation, the cumulative rates of VA-related hospitalizations were lower in the 2 years after their ablation procedure compared with the year before (rate ratio, 0.3; 95% confidence interval [CI], 0.22-0.43). Rates of CV-related hospitalization and hospitalization because of VA post index date were similar between the VT ablation and medical therapy groups (hazard ratio [HR], 0.94; 95% CI, 0.57-1.54 and HR, 1.04; 95% CI, 0.57-1.91, respectively). Health care costs in the VT ablation patients were not increased post-ablation compared with the medical management group. The risk of all-cause mortality was lower among patients in the VT ablation group relative to the medical therapy group (HR, 0.64; 95% CI, 0.4-0.99).Conclusions
Patients who underwent VT ablation experienced a significant reduction in their rate of VA-related hospitalizations. Patients treated with VT ablation had similar rates of CV-related hospitalization compared with those treated with medical therapy without increased health care-related costs. 相似文献3.
4.
Volker Heinemann Ludwig Fischer von Weikersthal Thomas Decker Alexander Kiani Florian Kaiser Salah-Edin Al-Batran Tobias Heintges Christoph Lerchenmüller Christoph Kahl Gernot Seipelt Frank Kullmann Markus Moehler Werner Scheithauer Swantje Held Lisa Miller-Phillips Dominik Paul Modest Andreas Jung Thomas Kirchner Sebastian Stintzing 《British journal of cancer》2021,124(3):587
Background Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab plus FOLFIRI in KRAS wild-type metastatic colorectal cancer (mCRC) in FIRE-3, but no corresponding benefit was found for progression-free survival. This analysis aimed to determine whether cetuximab improves response and survival versus bevacizumab among response-evaluable patients receiving first-line FOLFIRI for RAS wild-type mCRC and the effect of primary tumour side on outcomes.Methods The intent-to-treat population included 593 patients with KRAS exon 2 wild-type mCRC. Further testing identified 400 patients with extended RAS wild-type disease; of these, 352 (88%) who received ≥3 cycles of therapy and had ≥1 post-baseline scan were evaluable for response and constituted the per-protocol population (169 cetuximab and 183 bevacizumab). Patients received 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) with either weekly cetuximab or biweekly bevacizumab given on day 1 of each 14-day cycle until response, progression or toxicity occurred. The primary endpoint was the objective response rate (ORR) in the per-protocol population. Secondary endpoints included overall survival (OS) and progression-free survival (PFS). The effect of primary tumour location was evaluated.Results Median OS in the RAS wild-type population was 31 vs 26 months in the cetuximab and bevacizumab groups, respectively (HR 0.76, P = 0.012). In the per-protocol population, outcomes favoured cetuximab for ORR (77% vs 65%, P = 0.014) and median OS (33 vs 26 months, HR 0.75, P = 0.011), while PFS was comparable between groups. The advantage of cetuximab over bevacizumab occurred only in patients with left-sided primary tumours.Conclusions FOLFIRI plus cetuximab resulted in a significantly higher ORR and longer OS compared to FOLFIRI plus bevacizumab among patients with left-sided tumours. The superior response associated with cetuximab may particularly benefit patients with symptomatic tumours or borderline-resectable metastases.ClinicalTrials.gov identifier .Subject terms: NCT00433927Oncology, Biomarkers 相似文献
5.
6.
7.
8.
9.
10.
Die Anaesthesiologie - Das Management des schwierigen Atemwegs ist eine präklinische Schlüsselqualifikation. Für Notärzte mit hohem Erfahrungsgrad im Atemwegsmanagement sind... 相似文献